<DOC>
	<DOCNO>NCT00742625</DOCNO>
	<brief_summary>This phase II trial study side effect best dose bortezomib give together daunorubicin cytarabine see well work treat old patient previously untreated acute myeloid leukemia . Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , daunorubicin cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together combination chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Bortezomib , Daunorubicin , Cytarabine Treating Older Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To define remission induction response rate ( complete response [ CR ] CR incomplete platelet recovery [ CRp ] ) old patient previously untreated acute myeloid leukemia treat induction therapy comprise bortezomib combination daunorubicin hydrochloride cytarabine . II . To define maximum tolerate dose bortezomib administer combination intermediate-dose cytarabine induction therapy . SECONDARY OBJECTIVES : I . To describe disease-free survival patient treat regimen . II . To describe overall survival patient treat regimen . III . To evaluate treatment-related toxicity patient . OUTLINE : This multicenter , dose-escalation study bortezomib . Doses bortezomib escalate remission consolidation therapy . REMISSION INDUCTION THERAPY : Remission induction course 1 : Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 ; daunorubicin hydrochloride IV day 1-3 ; cytarabine IV continuously 168 hour day 1-7 . After completion remission induction course 1 , patient undergo bone marrow aspiration biopsy evaluation response . Patients achieve complete response ( CR ) partial response ( PR ) proceed remission consolidation therapy . Patients achieve CR incomplete platelet recovery ( CRp ) proceed remission consolidation therapy platelet count recover . Patients persistent leukemia ( &gt; = 20 % bone marrow cellularity &gt; = 5 % bone marrow myeloblast ) proceed remission induction course 2 . REMISSION INDUCTION COURSE 2 : Patients receive bortezomib IV 3-5 second day 1 4 ; daunorubicin hydrochloride IV day 1 2 ; cytarabine IV continuously 120 hour day 1-5 . After completion remission induction course 2 , patient undergo bone marrow aspiration biopsy evaluation response . Patients achieve CR PR proceed remission consolidation therapy . Patients achieve CRp proceed remission consolidation therapy platelet count recover . Patients residual leukemia meet criterion PR remove study . REMISSION CONSOLIDATION THERAPY : Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 intermediate-dose cytarabine IV 3 hour day 1-5 . Patients undergo bone marrow aspiration biopsy evaluation response . Patients achieve CR demonstrate continue CR receive second course remission consolidation therapy begin 2-4 week blood count recover . After completion study therapy , patient follow every 2 month 2 year , every 3 month 2 year , annually 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Unequivocally histologically confirm acute myeloid leukemia ( AML ) At least 20 % blast bone marrow base WHO criteria No acute promyelocytic leukemia ( M3 ) Antecedent hematologic disorder myelodysplastic syndrome allow provided patient receive cytotoxic chemotherapy , include azacitidine decitabine , preleukemic disorder Concurrent enrollment CALGB8461 require Not pregnant nursing Fertile patient must use effective contraception No ataxia , cranial neuropathy , peripheral neuropathy &gt; = grade 2 LVEF &gt; = 40 % ECHO MUGA scan No sign symptom congestive heart failure DLCO &gt; = 50 % ( correct hemoglobin ) No prior therapy leukemia preleukemic disorder , except follow : emergency leukapheresis ; emergency treatment hyperleukocytosis hydroxyurea ; cranial radiotherapy CNS leukostasis ( one dose ) ; growth factor/cytokine support No concurrent chemotherapy , except follow : I ) steroid administer adrenal failure , hypersensitivity reaction , septic shock ; II ) hormone administer nondiseaserelated condition ( e.g. , insulin diabetes estrogens progestin gynecologic indication ) No concurrent palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>